Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2]. Core Viewpoints - The report emphasizes that policy support for listed companies through mergers and acquisitions is crucial for high-quality development, leading to ongoing industry consolidation [5][14]. - The pharmaceutical and biotechnology sector has shown a weekly increase of 1.13%, outperforming the CSI 300 index by 0.25 percentage points, ranking 17th among 31 sub-industries [7][18]. Summary by Sections 1. Weekly Viewpoint - The report highlights that recent policies have improved regulatory inclusiveness and relaxed competition restrictions, facilitating mergers and acquisitions [14]. - Companies like Maipu Medical and Pilin Bio have announced plans for mergers and acquisitions, which are expected to enhance their technological capabilities and market positions [6][15]. 2. Subsector Performance - The pharmaceutical sector's sub-indices all recorded gains, with the raw materials and blood products sectors leading with a 2.89% increase [7][22]. - The report suggests that the medical device sector has significant room for valuation growth, with a current P/E ratio of 37.55, below its historical average [26]. 3. Recommended and Beneficiary Stocks - Recommended stocks include Yingke Medical, Maipu Medical, and Yihe Jiaye, among others [8]. - Beneficiary stocks identified are Shanhaishan, Yirui Technology, and Lianying Medical [27]. 4. Detailed Subsector Analysis - **Medical Devices**: The sector is expected to benefit from policies promoting equipment upgrades and procurement, with a focus on AI applications in imaging and surgery [26]. - **Medical Consumables**: The sector is projected to see steady growth as high-value consumables approach the end of their procurement cycle [29]. - **IVD Sector**: The report notes a 2.00% increase in the IVD sector, with a focus on AI-assisted diagnostics [30]. - **Blood Products**: The blood products sector is experiencing a 2.89% increase, with ongoing consolidation and product diversification [31]. - **Retail Pharmacy**: The offline pharmacy sector is expected to benefit from improved operational efficiencies through AI integration [34]. - **Healthcare Services**: The hospital sector has seen a 1.07% increase, with growth in specific medical fields like ophthalmology and reproductive health [36]. - **Traditional Chinese Medicine**: The sector is expected to recover as the impact of previous procurement policies diminishes [38]. - **CXO Sector**: The report indicates a positive outlook for the CXO sector, driven by increased demand for outsourcing in drug development [40].

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Viewpoints - The report emphasizes that policy support for listed companies through mergers and acquisitions is crucial for high-quality development, leading to ongoing industry consolidation [5][14] - The pharmaceutical and biotechnology sector has seen a weekly increase of 1.13%, outperforming the CSI 300 index by 0.25 percentage points, ranking 17th among 31 sub-industries [7][18] Summary by Sections 1. Weekly Viewpoint - The report highlights that recent policies have improved regulatory inclusiveness and relaxed competition restrictions, facilitating mergers and acquisitions [14] - Companies like Maipu Medical and Pilin Bio have announced plans for mergers and acquisitions, which are expected to enhance their technological capabilities and market positions [6][15] 2. Subsector Performance - The pharmaceutical and biotechnology sector has shown positive performance across all sub-sectors, with the raw materials and blood products sectors leading with a 2.89% increase [7][22] - The report suggests that the medical device sector has significant room for valuation growth, with a current P/E ratio of 37.55, below its historical average [26] 3. Recommended and Benefiting Stocks - Recommended stocks include Yingke Medical, Maipu Medical, and Yihua Jiaye, among others [8] - Benefiting stocks from the current trends include Shanhaishan, Yirui Technology, and Lianying Medical [8][27] 4. Detailed Subsector Analysis - **Medical Devices**: The sector is expected to benefit from policies promoting equipment upgrades and procurement, with a focus on AI integration in imaging and surgical applications [26] - **Medical Consumables**: The sector is projected to see steady growth as high-value consumables approach the end of their procurement cycle [29] - **IVD Sector**: The in vitro diagnostics sector is anticipated to recover as AI technologies enhance diagnostic capabilities [30] - **Blood Products**: The blood products sector is experiencing stable demand, with a projected 10.9% increase in plasma collection in 2024 [31] - **Retail Pharmacy**: The retail pharmacy sector is expected to see improved performance as market conditions stabilize and AI technologies enhance operational efficiency [34] - **Healthcare Services**: The healthcare services sector is showing signs of recovery, particularly in ophthalmology and reproductive health services [36] - **Traditional Chinese Medicine**: The sector is expected to benefit from improved consumer sentiment and demand for high-quality OTC products [38] - **CXO Sector**: The CXO sector is entering an upward cycle as companies report improved order growth and performance [40]

Core Viewpoint - The domestic chain pharmacy industry is experiencing significant challenges, transitioning from rapid expansion to a survival phase, with a focus on efficiency over scale [1][6][10]. Industry Overview - The chain pharmacy sector has shifted from a "land grab" phase to a "survival of the fittest" competition, with many stores closing or relocating due to poor performance [2][11]. - The number of retail pharmacies in China increased from 524,000 in 2019 to 667,000 in 2023, with projections of reaching 700,000 in 2024, indicating an oversupply situation [8][10]. Market Dynamics - In 2024, the number of closed pharmacies is expected to rise significantly, with quarterly closures projected at 6,778, 8,791, 9,545, and 14,114 respectively, marking the first negative growth in total pharmacy numbers in recent years [5][10]. - The rise of e-commerce and changing consumer habits have further pressured physical pharmacies, with online pharmacy sales expected to reach 75.8 billion yuan in 2024, growing by 14.4% year-on-year [8][10]. Financial Performance - In 2024, six listed chain pharmacy companies reported a collective decline in net profits, with only one company, Yifeng Pharmacy, showing growth [10][12]. - Major companies like Guoda Pharmacy have had to close numerous stores, with 1,273 direct stores and 389 franchise stores shut down in a short period [11][12]. Strategic Responses - To survive, many pharmacies are merging operations to reduce costs, with smaller chains collaborating to manage resources more efficiently [11][12]. - Major chains are adopting new strategies, including closing unprofitable stores and slowing expansion, as seen with Yifeng Pharmacy closing 1,078 stores in 2024 [12]. Future Directions - The future of pharmacies lies in diversification and service enhancement, with a shift towards health services beyond just selling medications [15][16]. - Companies are exploring models like "pharmacy + clinic" and expanding product offerings to include health-related items, aiming to create a more comprehensive service environment [15][16].

Group 1 - The company will implement a cash dividend of RMB 0.40 per share (including tax) to all shareholders based on the total share capital registered on the dividend distribution date, without issuing bonus shares or capital reserve transfers [1][2] - The company's dividend payout ratio for 2024 will be 51.56%, considering the cash dividends already distributed in the first half of 2024 [1] - The convertible bonds "Yifeng Convertible Bonds" will suspend conversion from June 11, 2025, until the dividend distribution date, after which conversion will resume [2] Group 2 - The company will disclose the implementation announcement of the dividend distribution and the adjustment of the convertible bond conversion price on June 12, 2025 [2] - The total distribution amount will be adjusted if the conversion of the convertible bonds leads to a change in the company's total share capital, while maintaining the per-share distribution ratio [1][2] - The company has provided contact information for inquiries regarding the dividend distribution and convertible bonds [2]

| 证券代码：603939 | 证券简称：益丰药房 公告编号：2025-051 | | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | 因益丰大药房连锁股份有限公司（以下简称"公司"或"本公司"）实施 2024 年 度权益分派,本公司的相关证券停牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 113682 | 益丰转债 | 可转债转股停 | 2025/6/11 | | | | | | | 牌 | | | | | 注：停牌终止日及复牌日可在公司后续发布的"益丰转债"转股价格调整公告中查阅。 一、2024 年年度权益分派方案的基本情况 2025 年 5 月 29 日，公司 2024 年年度股东会审议通过了《关于 2024 年度利润分配预 案的议案》，决定以实施权益分派股权登记日登记的普通股总股本为基数，向全体股东每 股派发现金红利人民币 0.40 元（含税），不送红股，不进行资本公积金转增股本。叠加 2024 年中期已 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-052 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●被担保人名称：湖南九芝堂零售连锁有限公司（以下简称"九芝堂零售"）， 为益丰大药房连锁股份有限公司（以下简称"公司"或"本公司"）合并报表范 围内子公司。 ●对外担保的逾期累计数量：无 一、担保情况概述 1、担保基本情况及履行决策程序 公司于 2024 年 9 月 12 日召开的第五届董事会第七次会议与 2024 年 9 月 23 日召开的 2024 年第三次临时股东大会审议通过了《关于为子公司申请银行授信 提供担保的议案》。九芝堂零售因经营发展需要，向银行申请综合授信额度，公 司对其授信进行担保，新增担保总额合计 16,000.00 万元。 2、本次担保情况如下： 单位：万元 | 担保方 | 被担保方 | 担保 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-050 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于使用闲置募集资金委托理财到期赎回 并继续委托理财的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 本次赎回产品名称：共赢智信汇率挂钩人民币结构性存款 A02288 期 （6,000.00 万），点金系列看涨两层区间 39 天结构性存款（1,000.00 万）。 赎回金额：7,000.00 万元 本次继续委托理财金额：6,000.00 万元 已履行的审议程序：经公司第五届董事会第十五次会议审议通过，同意在 确保不变相改变募集资金用途与不影响募集资金投资项目正常运行的情况下，使 用最高额度不超过 30,000.00 万元募集资金进行委托理财，用于购买安全性高、 流动性好的理财产品，自董事会审议通过起 12 个月有效，在上述额度与有效期 限内，购买理财产品资金可循环滚动使用。 特别风险提示 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][5] Core Views - The company is experiencing stable revenue growth, with a profit turning point already evident [1] - Revenue forecasts for 2025-2027 have been adjusted downwards, while net profit estimates have been revised upwards [2] - The target price is set at 19.74 CNY, based on a PE valuation of 21X for 2025 [2] Financial Performance Summary - For 2023, the company achieved a revenue of 24,531 million CNY, with a year-on-year growth of 15.5% [4] - The projected revenues for 2024, 2025, 2026, and 2027 are 26,497 million CNY, 29,649 million CNY, 33,012 million CNY, and 36,383 million CNY respectively, with growth rates of 8.0%, 11.9%, 11.3%, and 10.2% [4] - The company's net profit attributable to the parent company for 2023 was 1,166 million CNY, with a projected increase to 1,073 million CNY in 2025 [4] - The gross margin is expected to stabilize around 35% in the coming years, with a slight decrease in 2024 [4] Business Expansion and Strategy - The company continues to expand its retail business, with a significant increase in the number of stores, including 907 new self-built stores and 420 acquired stores in 2024 [9] - The retail business generated 219.2 billion CNY in 2024, accounting for 82.7% of total revenue, with a gross margin of 36.6% [9] - The company is actively developing its new retail business, achieving an 80.4% coverage rate for O2O delivery services by the end of 2024 [9]

Investment Rating - The report maintains a "Buy" rating for the company [2][5] Core Views - The company is experiencing stable revenue growth, with a profit turning point already evident [1] - Revenue forecasts for 2025-2027 have been adjusted downwards, while sales expense ratios have been increased, predicting net profits of 1.073 billion, 1.247 billion, and 1.395 billion yuan respectively for those years [2] Financial Performance Summary - **Revenue**: - 2023A: 24.531 billion yuan, 2024A: 26.497 billion yuan (YoY +8.0%), 2025E: 29.649 billion yuan (YoY +11.9%) [4] - **Net Profit**: - 2023A: 1.166 billion yuan, 2024A: 915 million yuan (YoY -21.6%), 2025E: 1.073 billion yuan (YoY +17.3%) [4] - **Earnings Per Share**: - 2023A: 1.02 yuan, 2024A: 0.80 yuan, 2025E: 0.94 yuan [4] - **Gross Margin**: - 2023A: 35.9%, 2024A: 34.3%, 2025E: 35.0% [4] - **Net Margin**: - 2023A: 4.8%, 2024A: 3.5%, 2025E: 3.6% [4] - **Return on Equity**: - 2023A: 17.9%, 2024A: 13.3%, 2025E: 14.3% [4] Business Expansion and Strategy - The company opened 907 new self-built stores and acquired 420 stores in 2024, with a total of 16,553 stores by the end of the year [9] - Retail business revenue reached 219.2 billion yuan in 2024, driven by the expansion of direct-operated stores and new openings [9] - The company is actively developing new retail business, achieving an 80.4% coverage rate for O2O delivery services by the end of 2024 [9]

Core Insights - The AMAC Wholesale Retail Trade Index (AMAC批零, H11045) increased by 1.3%, closing at 1617.5 points with a trading volume of 31.254 billion [1] - Over the past month, the index has risen by 2.93%, by 1.85% over the last three months, and by 0.73% year-to-date [1] Index Composition - The AMAC Wholesale Retail Trade Index is based on 43 industry classification indices, excluding manufacturing, and is compiled according to the classification guidelines from the China Securities Association [1] - The top ten weighted stocks in the index are: Huadong Medicine (5.33%), Yonghui Supermarket (3.05%), Digital China (2.87%), Shanghai Pharmaceuticals (2.83%), Wancheng Group (2.26%), Wuchan Zhongda (2.21%), Yifeng Pharmacy (2.19%), Jiuzhoutong (1.83%), Sinopharm (1.58%), and Kidswant (1.57%) [1] Market Distribution - The market distribution of the AMAC Wholesale Retail Trade Index shows that the Shenzhen Stock Exchange accounts for 53.12%, while the Shanghai Stock Exchange accounts for 46.88% [1] Industry Breakdown - In terms of industry composition, discretionary consumption accounts for 36.90%, healthcare for 31.52%, industrials for 22.28%, staples for 4.58%, energy for 2.78%, real estate for 1.27%, and financials for 0.67% [2]